by James Rudge, PhD, Technical Director, Neoteryx | 8 min read
An article published by Nils T. Vethe et al in the October 2019 issue of Therapeutic Drug Monitoring, reported on the successful validation of 10 µL Mitra® devices from 26-27 …
Read Storyby Neoteryx | 5 min read
According to a 2014 study, the cost of developing a new drug is $2.6 billion. This high expense doesn’t include the additional cost of post-approval development to determine dosage strengths …
Read Storyby Neoteryx | 2 min read
Therapeutic drug monitoring (TDM) helps in managing patients who are undergoing psycho-pharmacotherapy. TDM is essential in preventing therapeutic nonresponse and adverse drug reactions. It also enables dose adjustment, determination of …
Read Storyby Neoteryx | 3 min read
Just like every other industry, the healthcare sector continues to experience drastic changes. With each new year, it helps to identify the trends that are likely to shape the industry …
Read Storyby Neoteryx | 5 min read
Times have changed, and so has the average healthcare consumer. Today’s consumers are more inclined toward digital health solutions, particularly the younger generations. A survey from Accenture found millennials (born …
Read Storyby Neoteryx | 4 min read
What is occupational exposure? Millions of people are exposed to chemicals or other hazardous materials in their workplace every day. If not handled safely, these hazards can cause health problems …
Read StoryLearn about insights, research, case studies, and tutorials on integrating remote specimen collection, microsampling, and more!
© Neoteryx 2021 | Privacy Policy | Sitemap
421 Amapola Ave
Torrance, CA 90501
This site is protected by reCAPTCHA and the Google Privacy
Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.
Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.